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Background: The bile canaliculus is the smallest and first biliary channel and is formed by 
two or three adjacent hepatocytes. Previous studies of chronic cholangiopathies such as 
primary sclerosing cholangitis have focused on the bile ductules. However, little is known 
about the pathological alterations in bile canaliculi in the early phase of cholangiopathies. 
Aim: To characterize the bile canalicular morphology in the early phase of sclerosing 
cholangitis we used 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced mouse model of 
sclerosing cholangitis. 
Methods: Mice were fed a diet with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (0.1%). 
Serum biochemical, histological, immunohistochemical, and electron microscopic analyses 
were performed 1, 2, 4, and 7 days after feeding. 
Results: All experimental groups showed significantly increased serum aspartate 
aminotransferase, alanine aminotransferase, and alkaline phosphatase levels. From day 1, bile 
canalicular abnormalities such as dilatation and meandering and loss of microvilli were 
observed. After bile canalicular abnormalities had appeared, substantial infiltration of 
inflammatory cells was observed amongst the necrotic cells and periductal region. After these 
inflammatory changes, cholangiocytes proliferated in the portal area and formed ductular 
reactions. Finally, periductal fibrosis appeared. 
Conclusion: This study provides novel evidence of the occurrence of bile canalicular 
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abnormalities during the early phase of sclerosing cholangitis. 
 





1.  Introduction 
The bile canaliculus is the smallest and first biliary channel and is formed by two or three 
adjacent hepatocytes [1]. Bile canaliculi are located in the liver parenchyma and directly 
receive bile secreted by the hepatocytes. The bile canaliculi are exposed to and injured by 
toxic bile acids before the cholangiocytes in the bile ductules located in the portal area are 
injured by these bile acids. However, little is known about the pathological alterations of the 
bile canaliculi during the early phase of cholangiopathies. Bile is a complex solution 
consisting of inorganic and organic compounds including bile acids [2-4]. Even in normal 
conditions, bile acids are considerably toxic and directly induce cholangiocyte injury. 
Cholangiocytes construct bile ducts such as Hering’s canals, bile ductules, and intra- and 
extra-hepatic biliary ducts. Previous reports have demonstrated that bile injures 
cholangiocytes during its drainage through these ducts from the liver parenchyma to the 
duodenum, leading to chronic cholangiopathies [56]. 
Chronic cholangiopathies such as primary sclerosing cholangitis (PSC) and primary biliary 
cirrhosis (PBC) are characterized by chronic bile duct injury. In previous reports, the 
cholangiocytes of the bile ducts have been assumed to play a central role in the pathogenesis 
of these diseases as a primary target and also by inducing inflammation and fibrosis [7]. 
Cholangiocytes are injured by hydrophobic bile acids because the bile acids are directly toxic 
to cholangiocytes [8]. In addition, cholangiocytes that are activated (reactive cholangiocytes) 
5 
 
by toxic bile acids release proinflammatory cytokines, which then activate neutrophils, 
Kupffer cells, T cells, and natural killer cells. Simultaneously, activated cholangiocytes 
proliferate, leading to increased numbers of bile ductules. These reactions of cholangiocytes 
are referred to as ductular reactions (reactive cholangiocyte phenotype) [5, 9]. During the 
chronic phase, reactive cholangiocytes play a role in reparative and fibrogenic processes, 
leading to periductal fibrosis and eventually, biliary cirrhosis. During this phase, they release 
profibrogenic cytokines that affect hepatic stellate cells and portal fibroblasts, which 
differentiate into myofibroblasts that produce excess amounts of collagen fibers and 
extracellular matrix. Thus, previous studies have proposed that ductular reactions and portal 
fibrosis play a central role in cholangiopathies, but the role of bile canaliculi in the 
parenchyma remains unknown. 
Most data regarding the pathogenesis of cholangiopathies are derived from in vivo studies 
using animal models such as bile duct-ligated or carbon tetrachloride-treated rodents [10-11]. 
These models, however, are unsuitable for studying the early phase of cholangiopathies 
because the animals deteriorate rapidly, and the reproducibility of these models is low. To 
explore the pathological changes in bile canaliculi during the earlier phase, a gradually 
progressing cholangiopathy model is needed. Recently, Fickert et al. demonstrated that 
continuous feeding of mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) induces 
chronic cholangiopathy with an indolent course. This model is well established for studying 
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the mechanisms of sclerosing cholangitis [12] and is expected to be suitable for investigating 
the precise events that occur during the early phase of cholangiopathies including sclerosing 
cholangitis. 
Most patients with cholangiopathies display a progressive course and high mortality, and 
current therapeutic options for cholangiopathies are limited. Ursodeoxycholic acid (UDCA) 
is the most commonly used agent for treating cholangiopathies, and several studies have 
reported its effects in humans and rodents [13-16]. UDCA stimulates excretion of bile acids, 
other organic anions (e.g., bilirubin), and HCO3− from hepatocytes into bile canaliculi by 
transporter proteins. The therapeutic effects are noticeably greater during the early phase than 
the chronic phase [1718]. Therefore, elucidating bile canalicular changes during the early 
phase is extremely important for developing a therapeutic strategy for treating 
cholangiopathies. 
Here we explored the bile canaliculi in DDC-fed mice to characterize the morphological 
changes that occur during the early phase of cholangiopathy. This study will expand our 
understanding of the pathogenesis of cholangiopathies, and it may ultimately lead to novel 
therapeutic strategies. 
 





Various stains and genders of mice are differentially susceptible to DDC [19-20]. BALB/c 
mice display relatively slow progression and an intermediate degree of pathological changes 
[19]. Thus, to observe the morphological changes during the early phase (the first 7 days), 
male BALB/c mice that were 2 to 3 months old and weighing 25-30 g were used for all 
experiments, and age-matched BALB/c mice served as controls. To induce sclerosing 
cholangitis, mice were fed a diet containing 0.1% DDC (Sigma-Aldrich, St. Louis, USA) for 
1, 2, 4, and 7 days. Control mice were fed a standard mouse diet. The animals were sacrificed 
after these times, and blood was collected from the heart. For light and electron microscopic 
analyses, mice were perfused for 1 min with saline and fixed by transcardial (about 100 
mmHg) perfusion with 10% buffered formaldehyde or 2% glutaraldehyde. At least six mice 
were treated and analyzed per time period. All mice were housed individually in cages under 
specific pathogen-free conditions. All experimental protocols were approved by the local 
Animal Care and Use Committee, according to the criteria outlined in the Guide for the Care 
and Use of Laboratory Animals prepared by the National Academy of Sciences, as published 
by the National Institutes of Health (NIH, 1996) [21]. 
 
2.2. Serum Biochemical Analysis 
Serum samples were stored at −80 C until analyses of aspartate aminotransferase (AST), 
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alanine aminotransferase (ALT), and alkaline phosphatase (ALP) with a Hitachi 7180 
analyzer (Hitachi, Tokyo, Japan). 
 
2.3. Histopathology 
Pieces of liver were perfusion fixed in 10% neutral buffered formaldehyde and embedded 
in paraffin. Sections were cut 4 μm thick and stained with hematoxylin and eosin (H&E), 
Azan, or periodic acid Schiff (PAS) for histological evaluation of liver necrosis, inflammation, 
fibrosis, and glycogen stores. Liver inflammatory activity represents the grade of 
involvement, and fibrosis represents the stage of involvement. Grading of periportal interface 
hepatitis and portal inflammation and staging of fibrosis were performed according to the 
Ishak system [22]. Quantification of cytokeratin (CK)-positive cells was performed in 10 
portal tracts with portal veins measuring 50–150 μm in diameter. Quantification of 
Ki67-positive cells was performed in 10 randomly selected bile ductules, and quantification 
of focal necrotic cells was performed in 10 randomly selected areas in each specimen at a 
magnification ×400. Histology of specimens was assessed by a pathologist (HK) who was 
blinded to the treatment. 
 
2.4. Immunohistochemical Studies 
Immunohistochemical staining of specimens was performed according to the 
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manufacturer’s instructions. Briefly, antigen retrieval was carried out in a pressure cooker by 
boiling in 10 mM citrate buffer (pH 6.0), followed by washing with phosphate-buffered saline 
(PBS). Endogenous peroxidase was then quenched with 3% H2O2 for 10 min at room 
temperature. After rinsing, slides were treated overnight at 4 °C with negative control reagent 
or the following optimally diluted primary antibodies: carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1; mouse monoclonal; 1:400; eBioscience, San Diego, USA), 
α-smooth muscle actin (αSMA; rabbit polyclonal; 1:400; Abcam, Cambridge, USA), 
pancytokeratin (rabbit polyclonal; prediluted; Nichirei, Tokyo, Japan), and Ki67 (mouse 
monoclonal; 1:100; Novocastra, Newcastle, UK). Slides were incubated with anti-mouse and 
anti-rabbit horseradish peroxidase-conjugated secondary antibody (goat polyclonal; 
prediluted; MBL, Nagoya, Japan). Binding to the antibody was detected using the labeled 
polymer method. Diaminobenzidine (MBL) was used as the chromagen, followed by 
counterstaining with hematoxylin. 
 
2.5. Transmission and scanning electron microscopic analyses 
Perfusion-fixed livers were cut into 1-mm sections for transmission electron microscopy 
(TEM) and into 2-mm sections for scanning electron microscopy (SEM). These sections were 
immersion fixed in 2% glutaraldehyde at 4 °C for 2 hours. The specimens for TEM were 
extensively washed with PBS, postfixed in 1% osmium tetroxide, dehydrated in a graded 
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series of ethanol, and embedded in Epon. Ultra-thin sections (80 nm) were cut on an Ultra 
microtome EM UC6 (Leica, Vienna, Austria), stained with 1% uranyl acetate, counterstained 
with the Reynolds method, and examined on an H-7650 electron microscope (Hitachi). The 
specimens for SEM were postfixed in 1% osmium tetroxide, dehydrated in a graded series of 
ethanol, and dried. The sections were then coated with a thin layer of platinum/palladium and 
visualized under an S-4700 electron microscope (Hitachi). 
 
2.6. Statistical Analysis 
Data are reported as the arithmetic means ± SE of six animals in each group. Data were 
analyzed with SPSS version 20 Software (SPSS, Tokyo, Japan). The statistical significance 
was determined with the Mann-Whitney U test with Bonferroni correction for multiple 
comparisons. A P-value <0.05 was considered significant. 
 
3.  Results 
3.1. DDC feeding induces cholestasis and hepatomegaly during the early phase of sclerosing 
cholangitis 
 
To elucidate the morphological and functional changes during the early phase of 
DDC-induced sclerosing cholangitis, we obtained tissue samples during the first 7 days of 
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DDC feeding. We first performed serum biochemical and macroscopic analyses. Compared 
with control mice, all DDC-fed mice showed significantly increased serum AST and ALT 
levels (Control AST level (0 day): 206.3 ± 46.2; Control ALT level: 35.2 ± 2.2), indicating 
hepatocyte injury (Fig. 1A and B). The ALP level, an indicator of the degree of cholestasis, 
was significantly elevated in DDC-treated mice in a time-dependent manner (Control ALP 
level: 190.5 ± 13.2) (Fig. 1C). Macroscopically, even after only 1 day of DDC feeding, the 
skin of the ears, paws, and tail of DDC-fed mice showed yellowish coloration, indicating 
jaundice (data not shown). Within 7 days of DDC feeding, the liver was clearly enlarged and 
showed brown discoloration; the gallbladder showed dark bile and gallstones (Fig. 2A and C). 
Control liver and gallbladder were normal in appearance (Fig. 2A and B). The liver 
weight/body weight ratio (LW/BW) was significantly increased in a time-dependent manner 
from day 2 (Control LW/BW (%): 4.67 ± 0.26) (Fig. 2D). On the other hand, no significant 
difference was seen in the spleen weight/body weight ratio (SW/BW), an indicator of portal 
hypertension (Control SW/BW (%): 0.46 ± 0.03) (Fig. 2E).  
To further evaluate the morphological changes during the first 7 days, we next performed 
light microscopic, TEM, and SEM analyses. Histologically, porphyrin pigment plugs in bile 
canaliculi and bile ductules were observed beginning on day 1 of DDC feeding 
(Supplementary Fig. 1A). These plugs were also seen with TEM analysis (Supplementary Fig. 
1B). Focal hepatocellular necrosis was observed beginning on day 1 and was prominent at 
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days 1 and 2 compared with days 4 and 7 (Fig. 3A and B). Phagocytosis of these necrotic 
cells by polymorphonuclear neutrophils (PMNs) and Kupffer cells was confirmed with H&E 
staining and TEM analysis (Fig. 3A, Supplementary Fig. 2A and B). PAS staining showed 
marked depletion of glycogen in DDC-fed mice (Supplementary Fig. 3), which was most 
prominent at day 1. TEM also showed reduced glycogen particles (data not shown). 
Immunohistochemical staining with anti-Ki67 showed significantly increased numbers of 
Ki67-positive hepatocytes at days 2, 4, and 7, which indicates compensatory hepatocyte 
proliferation (Supplementary Fig. 4). At days 2, 4, and 7, obvious inflammatory cell 
infiltration followed by interface hepatitis was observed in the portal area (Fig. 3A, C, and D). 
These inflammatory cell infiltrates were also seen with TEM and SEM (data not shown). 
 
3.2. DDC feeding induces bile canalicular abnormalities during the early phase of sclerosing 
cholangitis 
We hypothesized that morphological changes in bile canaliculi that are associated with 
hepatocellular damage appear during the early phase of cholangiopathy pathogenesis. We 
therefore performed CEACAM1 immunostaining to observe bile canalicular changes during 
the first 7 days of DDC feeding [23-24]. In control mice, anti-CEACAM1 antibody labeled 
bile canaliculi in the liver parenchyma, whereas the antibody did not label sinusoids (Fig. 4). 
The bile canaliculi demonstrated double contours, were aligned in orderly lines, and showed 
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a “chicken-wire”-like appearance in control mice (Fig. 4 and Supplementary Fig. 5) [25]. In 
contrast, after 1 day, the bile canaliculi were dilated and showed meandering lines. This 
aberrant arrangement was augmented in a time-dependent manner (Fig. 4). The 
immunoreactivity intensity was reduced over time, and the reduction was prominent in Zone 
3 (pericentral vein zone) compared with Zone 1 (periportal zone) (Supplementary Fig. 5). 
This difference in immunoreactivity between Zone 1 and Zone 3 may be due to susceptibility 
to toxic effects [26].  These bile canalicular abnormalities were also confirmed with SEM 
and TEM (Fig. 4). SEM and TEM analyses also revealed loss of microvilli (Fig. 4), irregular 
protrusions of cytoplasmic membranes, and aberrantly arranged tight junctions 
(Supplementary Fig. 6). 
 
3.3. Bile canalicular abnormalities precede ductular reactions and periductal fibrosis in 
DDC-induced sclerosing cholangitis 
Bile canalicular abnormalities such as dilatation and meandering appeared beginning on 
day 1 of DDC feeding as demonstrated above, whereas most previous reports state that the 
primary injury in cholangiopathies including PSC occurs in bile ductules that are located in 
the portal area. To study the timing of when the ductular reactions appear in DDC-induced 
sclerosing cholangitis, we performed immunohistochemical staining for cholangiocytes in 
bile ductules with anti-CK and anti-Ki67 antibodies. We observed no apparent change in 
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morphology or numbers of bile ductules in control mice and at days 1 and 2 after DDC 
feeding (Fig. 5A-C). However, at days 4 and 7, ductular reactions were seen (Fig. 5A). The 
numbers of CK- and Ki67-positive cells at days 4 and 7 were significantly increased 
compared with control mice and DDC-fed mice after 1 and 2 days (Fig. 5B and C). 
Consistent with these findings, αSMA-positive cells (myofibroblasts) were significantly 
increased at days 4 and 7 (data not shown). SEM and TEM analyses also showed increased 
numbers of bile ductules with irregular cilia and irregular protrusions of cytoplasmic 
membranes (Supplementary Fig. 7A and B). 
To observe the timing when periductal fibrosis appears in DDC-induced sclerosing 
cholangitis, we performed Azan staining. Periductal fibrosis appeared on day 7, whereas 
control mice and mice fed DDC for 1, 2, and 4 days showed no fibrotic changes (Fig. 3A and 
E). SEM and TEM analyses confirmed the increased numbers of collagen fibers in periductal 
areas on day 7 (data not shown). 
 
3.4. DDC feeding induces sinusoidal capillarization and intracellular organelle injury 
Bile canalicular (apical side of hepatocytes) abnormalities appeared earlier in 
DDC-induced sclerosing cholangitis than ductular reactions and periductal fibrosis. The bile 
canaliculi are formed by the apical membranes of hepatocytes. To further address the effects 
of DDC in other regions of hepatocytes, sinusoids (basal/lateral side of hepatocytes) and 
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intracellular organelles were evaluated by SEM and TEM analyses. SEM and TEM showed 
depletion of pores in sinusoids, an increase in collagen fibers, and the deposition of debris in 
the space of Disse at days 4 and 7 (Fig. 6). Increased collagen fibers were not detected with 
Azan staining (Fig. 3A). In contrast, control mice and mice fed DDC for 1 and 2 days did not 
show these findings. These results indicate that sinusoidal capillarization, debris deposition, 
and pericellular fibrosis appeared during the first 7 days of DDC feeding. DDC-fed mice also 
showed increased numbers of abnormal intracellular organelles such as irregularly shaped 
mitochondria with fractured cristae, autophagosomes, distended Golgi apparatuses, and 
endoplasmic reticula with dilated cristae (Supplementary Fig. 8). 
 
4.  Discussion 
We provide the first evidence showing that bile canalicular abnormalities appear prior to 
ductular reactions in a DDC-induced sclerosing cholangitis model. Using a bile duct-ligated 
rodent model, ductular reactions have been reported to occur early in cholangiopathy [27-30]. 
The bile duct-ligated rodent model seems unsuitable for studying the early phase of 
cholangiopathies. Rodents subjected to this treatment show rapid deterioration and 
development of ductular reactions within a few days. Consequently, there is not enough time 
to evaluate the morphological changes that occur before the ductular reactions appear. In 
contrast, the DDC-induced mouse model used in this study shows slow disease progression. 
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This model provides sufficient time to explore the early phase of cholangiopathies and may 
accurately reflect the early phase of human cholangiopathies such as PSC and PBC. 
For pathological diagnosis with liver specimens biopsied from patients with liver diseases, 
estimation of the intensity of inflammation is evaluated by examining the inflammatory cells 
in the portal area (portal inflammation) and the destruction of hepatocytes lining the interface 
between the portal area and the parenchyma (interface hepatitis) [22]. We explored portal 
inflammation and interface hepatitis that appeared during the first 7 days after DDC feeding 
and demonstrated that these inflammatory changes appeared after the morphological 
abnormalities in bile canaliculi. These results indicate that the observation of bile canaliculi 
may be useful for early diagnosis rather than observations of portal and interface regions. It is 
difficult for pathologists to evaluate bile canaliculi on routine H&E sections. To evaluate the 
morphological changes in bile canaliculi, we used anti-CEACAM1 antibody, which is 
specific for bile canaliculi in the human liver [24]. CEACAM1 is one of the few CEA family 
members and is highly expressed in bile canalicular membranes in the mature liver of rodents 
and human [24, 31-32]. Our immunohistochemistry data clearly revealed that the bile 
canaliculi injured by DDC showed dilatation and meandering lines (Fig. 4). The 
anti-CEACAM1 antibody may be useful for the early diagnosis of cholangiopathies in the 
clinical setting. 
The morphological changes observed in bile canaliculi during the early phase of 
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cholangiopathies as shown in this study may lead to earlier diagnosis in clinical settings such 
as follow-up biopsy after liver transplantation and in familial cholangiopathies. Early 
diagnosis can prevent progression of cholangiopathies with the use of appropriate therapies. 
Recently, several therapeutic agents such as INT-767, β-adrenoceptor, 24-norUDCA, 
curcumin, and darbepoetin have been developed for treating cholangiopathies [33-38]. The 
therapeutic effects of these agents as well as UDCA are greater during the early phase than 
during the chronic phase. Therefore, early diagnosis by detecting the morphological changes 
shown in our study and the early initiation of treatments using these agents may improve the 
outcome in patients with cholangiopathies. 
This study demonstrated some electron microscopic findings in addition to the appearance 
of bile canaliculi during the early phase of cholangiopathy. We observed significantly reduced 
numbers of pores in sinusoids, pronounced deposition of debris in the space of Disse, 
irregular protrusion of cytoplasmic membranes in bile ductules and bile canaliculi, and 
irregularly shaped cilia. The significantly reduced numbers of pores in sinusoids and the 
pronounced deposition of debris in the space of Disse were found with SEM and TEM 
analyses beginning on day 4. Furthermore, significantly increased numbers of collagen fibers 
in the space of Disse were found at day 7. Xie et al. also reported that capillarization precedes 
fibrosis in a rat model of liver cirrhosis and suggested that sinusoidal endothelial cell 
differentiation is an integral part of the development of fibrosis [39]. To our knowledge, no 
18 
 
report has described a role for endothelial cells in the early phase of cholangiopathies. Such 
an observation in the DDC-induced model is a novel aspect of the early abnormalities in this 
disease. Lyoumi et al. observed irregular protrusions of the cytoplasmic membranes of 
cholangiocytes in the DDC-induced mouse model. However, no report has presented this 
finding in bile canaliculi (Supplementary Fig. 6A and 7B). These protrusions are likely 
formed in association with hepatocellular injuries, and further investigation of their 
pathological importance in cholangiopathies is required. The abnormal cilia in bile ductules 
(Supplementary Fig. 7A) have been described in previous reports studying biliary atresia, a 
type of congenital cholangiopathy [4041]. Philips et al. reported that abnormalities in cilia 
and canaliculi appear at a very early stage of embryonic liver development, suggesting that 
cholestasis develops in utero. Their results are consistent with those of our study, which 
revealed these abnormalities during the early phase of DDC-induced sclerosing cholangitis. 
Therefore, further investigation is necessary to elucidate the interaction of bile canaliculi and 
cilia during the early phase of cholangiopathies. 
We revealed that damage to various regions of hepatocytes such as the apical side (bile 
canaliculus), basal/lateral side (sinusoid), and intracellular organelles appeared during the 
first 7 days. We did not clarify the region of hepatocytes that was primarily injured by DDC. 
There are two possible mechanisms of damaging hepatocytes. One is the production of toxic 
bile acids via the hepatocytes that are stimulated by DDC. Toxic bile acids may directly 
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injure the bile canaliculi, and the damage would then spread to other regions in the 
hepatocytes. The other possibility is direct toxicity of DDC for hepatocytes entirely. In either 
case, the hepatocyte is the first target in DDC-induced sclerosing cholangitis. Together with 
the fact that the injury to bile canaliculi constructed by hepatocytes (bile canalicular 
abnormalities) precedes injury to bile ductules constructed by cholangiocytes (ductular 
reactions), ductular reactions are deemed to be a secondary phenomenon in cholangiopathies 
including PSC and PBC. Our study focused on the morphological alterations of hepatocytes, 
especially of bile canaliculi, and cholangiocytes. These observations are necessary for 
elucidating the precise pathogenesis in the early phase of cholangiopathies. 
In conclusion, we show that bile canalicular abnormalities precede ductular reactions in 
DDC-induced sclerosing cholangitis. In both human cholangiopathies such as PSC and PBC 
and rodent models, detailed morphological evaluation of bile canaliculi may help expand our 
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Fig. 1: Quantification of serum levels of (A) aspartate aminotransferase (AST), (B) alanine 
aminotransferase (ALT), and (C) alkaline phosphatase (ALP) in control (day 0) and 
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice. Data shown are expressed as the 
mean ± SEM from 6 mice per group. 
a
P <0.05 compared with control mice (day 0). 
b
P <0.05 
compared with DDC-fed mice (day 1). 
c
P <0.05 compared with DDC-fed mice (day 2). 
 
Fig. 2: (A) Macroscopic appearance of livers from control mice (left) and mice fed DDC for 
7 days (right). (B) Gallbladder of control mice. (C) Gallbladder of mice fed DDC for 7 days. 
(D) Liver weight/body weight (LW/BW) ratios of control (0 day) and DDC-fed mice. (E) 
Spleen weight/body weight (SW/BW) ratios of control and DDC-fed mice. Data shown are 
expressed as the mean ± SEM from 6 mice per group. 
a
P <0.05 compared with control mice 
(day 0). 
b
P <0.05 compared with DDC-fed mice (day 1). 
c
P <0.05 compared with DDC-fed 
mice (day 2). 
d
P <0.05 compared with DDC-fed mice (day 4). NS = not significant. 
 
Fig. 3: (A) Microscopic appearance of livers from control and DDC-fed mice. Left panels 
show H&E staining in the parenchyma. Arrowheads indicate focal necrotic hepatocytes with 
infiltration of polymorphonuclear neutrophils (PMNs) and Kupffer cells. (bars = 25 μm) 
Middle panels show H&E staining in the portal area. Portal inflammation and interface 
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hepatitis are seen in DDC-fed mice (days 4 and 7). Pigment plugs are found in mice fed DDC 
for 4 days. (bars = 25 μm) Right panels show Azan staining in the portal area. Fibrous 
expansion is seen in DDC-fed mice (day 7). (bars = 25 μm) (B) Histological grading of focal 
necrosis in control (0 day) and DDC-fed mice. (C) Histological grading of portal 
inflammation in control and DDC-fed mice. The bars indicate the mean histological grade of 
each group. (D) Histological grading of interface hepatitis in control and DDC-fed mice. (E) 
Histological staging of fibrosis in control and DDC-fed mice. Data shown are expressed as 
the mean ± SEM from 6 mice per group. 
a
P <0.05 compared with control mice (day 0). 
b
P 
<0.05 compared with DDC-fed mice (day 1). 
c
P <0.05 compared with DDC-fed mice (day 2). 
d
P <0.05 compared with DDC-fed mice (day 4). 
 
Fig. 4: The morphology of control bile canaliculi and morphological deterioration of the bile 
canaliculi from DDC-fed mice is shown. Column 1: Immunohistochemical staining for 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) (bars = 10 μm). 
Column 2: Low-magnification scanning electron microscopy (SEM) images (bars = 2 μm). 
Red arrowheads indicate bile canaliculi. Column 3: High-magnification SEM images (bars = 
500 nm). Column 4: Ttransmission electron microscopy (TEM) images (bars = 1 μm) of the 





Fig. 5:  (A) Immunohistochemical staining for cytokeratin (CK) (left panels) and Ki67 
(right panels) in control and DDC-fed mice (bars = 50 μm). (B) Quantification of 
CK-positive cells in 10 portal tracts with portal veins measuring 50–150 μm in diameter in 
control (0 day) and DDC-fed mice (left column). Quantification of Ki67-positive cells in 10 
randomly selected bile ductules in control and DDC-fed mice at ×400 magnification (right 
column). Data shown are expressed as the mean ± SEM from 6 mice per group. 
a
P <0.05 
compared with control mice (day 0). 
b
P <0.05 compared with DDC-fed mice (day 1). 
c
P 
<0.05 compared with DDC-fed mice (day 2). 
d
P <0.05 compared with DDC-fed mice (day 4). 
 
Fig. 6: The morphological changes in sinusoids and the space of Disse in control and 
DDC-fed mice (day 7) are shown. Column 1: Low-magnification SEM images (bars = 2 μm). 
Arrows highlight the sinusoidal space. Column 2: High-magnification SEM images (bars = 
500 nm). Arrowheads highlight the sinusoidal pores. Column 3: TEM images (bars = 1 μm). 
SEM shows a pronounced decrease in sinusoidal pores in DDC-fed mice (day 7). In the TEM 
image of DDC-fed mice, the arrow indicates debris in the space of Disse. 
 
